trending Market Intelligence /marketintelligence/en/news-insights/trending/o4r6IiN6TJHkMprQG_MW_w2 content esgSubNav
In This List

Novo Nordisk agrees to diabetes deal worth up to €350M

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Novo Nordisk agrees to diabetes deal worth up to €350M

Novo Nordisk A/S entered a licensing agreement with reMYND nv to develop its preclinical diabetes treatment.

The Danish heavyweight would potentially pay up to €350 million in research and milestone payments for ReS39, plus royalties.

ReS39 has been shown to sustain and increase the insulin production capacity of the pancreas in animals with type 1 and type 2 diabetes. The program also has the potential to treat nonalcoholic steatohepatitis — a chronic liver disease known as NASH — and metabolic syndrome because it reduces liver weight and triglyceride content.

The treatment is being profiled so that researchers can undertake preclinical toxicology studies.

reMYND was founded as a spinoff from Belgium's University of Leuven in 2002.